This inventor holds 4 USPTO granted patents. Top assignees: Teijin Limited, Teijin Pharma Limited. Active years: 2002-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Hino, JP (2002 - 2004)
- Yamaguchi, JP (2003 - 2015)
Company Filing History:
Years Active: 2002-2015
Title: Takayuki Hara: Innovator in Pharmaceutical Compounds
Introduction
Takayuki Hara is a notable inventor based in Yamaguchi, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on quaternary ammonium salt compounds and biphenylamidine derivatives. With a total of 4 patents to his name, Hara continues to push the boundaries of medicinal chemistry.
Latest Patents
Hara's latest patents include the development of quaternary ammonium salt compounds. The objective of this invention is to provide a novel compound that exhibits both β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity. The compounds are represented by a specific formula and include pharmaceutically acceptable salts that demonstrate superior activity in these areas. Additionally, he has worked on biphenylamidine derivatives, further showcasing his expertise in creating innovative pharmaceutical solutions.
Career Highlights
Throughout his career, Takayuki Hara has been associated with prominent companies such as Teijin Limited and Teijin Pharma Limited. His work in these organizations has allowed him to collaborate with other talented professionals and contribute to groundbreaking research in the pharmaceutical industry.
Collaborations
Hara has worked alongside notable colleagues, including Tomohisa Nakada and Yasunobu Takano. These collaborations have played a crucial role in advancing his research and patent developments.
Conclusion
Takayuki Hara is a distinguished inventor whose work in pharmaceutical compounds has made a significant impact in the field. His innovative patents and collaborations highlight his dedication to advancing medicinal chemistry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
